Evaluation of osteonectin as a diagnostic marker of osteogenic bone tumors

Serra, Massimo; Morini, Maria; Scotlandi, Katia; Fisher, Larry W.; Zini, Nicoletta; Colombo, Mario P.; Campanacci, Mario; Maraldi, Nadir M.; Olivari, Silvia; Baldini, Nicola

doi:10.1016/0046-8177(92)90050-d

Cited by 37 publications

(20 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…18,[35][36][37][38][39][40] Okada et al 41 studied eight cases of low-grade central osteosarcomas retrospectively and showed that proliferative cell activity evaluated by AgNOR and MIB-1 immunohistochemical staining was significantly higher in cases of low-grade central osteosarcoma than in fibrous dysplasia and might be helpful in differentiating low-grade central osteosarcoma from fibrous dysplasia. Pollandt et al 42 showed that Gsalpha gene mutations were a constant finding in cases of monostotic fibrous dysplasia.…”

Section: Discussionmentioning

confidence: 99%

MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone

Dujardin

Binh²,

Bouvier³

et al. 2011

Modern Pathology

192

122

View full text Add to dashboard Cite

Low-grade osteosarcoma is a rare malignancy that may be subdivided into two main subgroups on the basis of location in relation to the bone cortex, that is, parosteal osteosarcoma and low-grade central osteosarcoma. Their histological appearance is quite similar and characterized by spindle cell stroma with low-to-moderate cellularity and well-differentiated anastomosing bone trabeculae. Low-grade osteosarcomas have a simple genetic profile with supernumerary ring chromosomes comprising amplification of chromosome 12q13-15, including the cyclindependent kinase 4 (CDK4) and murine double-minute type 2 (MDM2) gene region. Low-grade osteosarcoma can be confused with fibrous and fibro-osseous lesions such as fibromatosis and fibrous dysplasia on radiological and histological findings. We investigated MDM2-CDK4 immunohistochemical expression in a series of 72 low-grade osteosarcomas and 107 fibrous or fibro-osseous lesions of the bone or paraosseous soft tissue. The MDM2-CDK4 amplification status of low-grade osteosarcoma was also evaluated by comparative genomic hybridization array in 18 cases, and the MDM2 amplification status was evaluated by fluorescence in situ hybridization or quantitative real-time polymerase chain reaction in 31 cases of benign fibrous and fibro-osseous lesions. MDM2-CDK4 immunostaining and MDM2 amplification by fluorescence in situ hybridization or quantitative real-time polymerase chain reaction were investigated in a control group of 23 cases of primary high-grade bone sarcoma, including 20 conventional high-grade osteosarcomas, two pleomorphic spindle cell sarcomas/malignant fibrous histiocytomas and one leiomyosarcoma. The results showed that MDM2 and/or CDK4 immunoreactivity was present in 89% of lowgrade osteosarcoma specimens. All benign fibrous and fibro-osseous lesions and the tumors of the control group were negative for MDM2 and CDK4. These results were consistent with the MDM2 and CDK4 amplification results. In conclusion, immunohistochemical expression of MDM2 and CDK4 is specific and provides sensitive markers for the diagnosis of low-grade osteosarcomas, helping to differentiate them from benign fibrous and fibro-osseous lesions, particularly in cases with atypical radio-clinical presentation and/or limited biopsy samples.

show abstract

Section: Discussionmentioning

confidence: 99%

MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone

Dujardin

Binh²,

Bouvier³

et al. 2011

Modern Pathology

192

122

View full text Add to dashboard Cite

show abstract

“…ON. Osteonectin has been reported to be present in fibroblasts, [34][35][36][37] although others have reported that fibroblasts, fat tissue, and skeletal muscle tissue are negative for osteonectin. 38 It seems likely that differences in antibody specificities, not antibody concentration, may account for some of these inconsistencies.…”

mentioning

confidence: 99%

Osteocalcin and Osteonectin Immunoreactivity in the Diagnosis of Osteosarcoma

et al. 1997

View full text Add to dashboard Cite

show abstract

“…Nevertheless, OCN is rarely used in clinical practice. ONN is a protein that is implicated in regulating the adhesion of osteoblasts and platelets to their extracellular matrix, as well as early mineralization and should only be used as part of a panel of reagents, directed at several lineage-related proteins (Serra et al, 1992;Wuisman et al, 1992).…”

Section: The Role Of Immunohistochemistry In the Diagnosis Of Osteosamentioning

confidence: 99%